rifaximin alfasigma 550 mg film-coated tablets
alfasigma s.p.a - rifaximin - film-coated tablet - 550 milligram(s) - antibiotics; rifaximin
lormyx 200 mg
megapharm ltd - rifaximine - film coated tablets - rifaximine 200 mg - rifaximin - rifaximin - • casual treatment of diseases of grown-ups and youngsters from 12 years up, caused by bacteria in the gastrointestinal tract, sensitive to rifaximin:• hepatic encephalopathy • traveller’s diarrhea, caused by not-invasive enteropathogeneous bacteria.• non-complicated diverticular diseases.
rifaximin alfa wasserman 550 milligram film coated tablet
alfa wassermann s.p.a. - rifaximin - film coated tablet - 550 milligram - antibiotics
rifaximin 550mg tablets
special order - rifaximin - oral tablet - 550mg
xifaxan rifaximin 550 mg tablet blister pack
norgine pty ltd - rifaximin, quantity: 550 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; titanium dioxide; glyceryl diisostearate; purified talc; hypromellose; propylene glycol; disodium edetate; colloidal anhydrous silica; iron oxide red; sodium starch glycollate type a - prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated.
xifaxan rifaximin 200 mg film-coated tablet blister pack
norgine pty ltd - rifaximin, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; glyceryl isostearate; sodium starch glycollate type a; colloidal anhydrous silica; purified talc; hypromellose; titanium dioxide; disodium edetate; propylene glycol; iron oxide red - xifaxan is indicated for the treatment of patients ( > = 12 years of age) with travellers? diarrhoea caused by non-invasive strains of escherichia coli (see ?precautions?, and ?clinical trials? ). travellers? diarrhoea describes a clinical picture predominantly observed in subjects travelling from developed to developing countries. it is most frequently caused by enterotoxigenic escherichia coli (etec), enteroaggregative e. coli (eaec) and other non-invasive pathogens.
rifaximina 550mg comprimidos recubiertos
laboratorios stein, s.a - rifaximina - rifaximina....550,0000 mg
xifaxan- rifaximin tablet
cardinal health 107, llc - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 550 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions (5.1), clinical pharmacology (12.4), clinical studies (14.1)]. xifaxan is indicated for re
xifaxan rifaximin tablet
carton service, incorporated - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 550 mg
xifaxan- rifaximin tablet
salix pharmaceuticals, inc. - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions ( 5.1), clinical pharmacology ( 12.4), clinical studies ( 14.1)]. x